Alzinova's strategy, to develop an effective and safe treatment for Alzheimer's disease that targets the toxic forms of amyloid beta, the oligomers, has been gaining interest. Preclinical data has documented "best in class" potential and clinical results from other actors in the field strengthens the Company's strategy. The Company will increase its participation at conferences, with the goal of establishing global partnerships.

International conferences:

AD/PD™ - International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, March 28 – April 1
AD/PD™ is an international conference on neurodegenerative diseases held in Gothenburg from 28 March to 1 April. The AD/PD™ conference has become a major event in the field of neurodegenerative diseases, attracting leading medical and scientific experts from around the world. AD/PD™ is an annual meeting focusing on advances in research and treatment for Alzheimer's, Parkinson's disease and other related neurological disorders. Alzinova will be there to network and present the Company's pharmaceutical projects to Key Opinion Leaders, potential licensees and partners. In conjunction with the conference, Alzinova's Chief Scientific Officer Anders Sandberg will present a scientific poster on the Company's vaccine candidate ALZ-101. Read more here: https://adpd.kenes.com/

Biotech International Convention - US BIO, June 5 – 8
The BIO International Convention is the world's largest meeting place for pharmaceutical and biotechnology companies, attracting over 14,000 leaders in the biotechnology and pharmaceutical industries to a week of intensive networking to discover new opportunities, enable collaborative and partner discussions and investor meetings. In total, over 3,000 companies participate from more than 30 countries. Alzinova's CEO, Kristina Torfgård and Business Development Director, Sebastian Hansson will meet potential partners from their global network in the pharmaceutical industry and establish new contacts with a focus on presenting and promoting the Company's pharmaceutical projects. Read more here: https://www.bio.org/events/bio-international-convention

For investors:

Redeye Theme: Alzheimer’s disease, March 15
Drug development in the field of Alzheimer's disease is an ongoing hot topic and society is now facing an important paradigm shift with the commercialisation of the first disease-modifying therapies. Redeye has invited Alzinova and two other companies - three prominent Swedish Alzheimer's companies - to a panel discussion to talk about the science behind their drug candidates, the remaining need and what it will take to successfully launch a new generation of Alzheimer's drugs. CEO Kristina Torfgård will participate in the panel. Read more here: https://www.redeye.se/events/875025/redeye-alzheimer-seminar

Mangold Insight Investor Day – Life Science, March 22
At Mangold Insight's investor day, Azinova's CEO Kristina Torfgård will present the Company and its latest developments. For more information: https://mangold.se/evenemang/mangold-insight-investerardag-22-mars/

Redeye Investor Forum Malmö, March 30
Redeye Investor Forum is a live broadcast where different companies give a 12-minute presentation followed by an 8-minute Q&A session moderated by Redeye analysts. Kristina Torfgård, CEO, will be in Malmö to present Alzinova's business. You can ask your questions directly to Alzinova during the live broadcast in the question form available on the event page: https://www.redeye.se/events/870674/investor-forum-malmo-5

Redeye Investor Forum Gothenburg, April 20
CEO Kristina Torfgård presents at Redeye Investor Forum in Gothenburg on 20 April. The event is a live broadcast where different companies will give a 12-minute presentation followed by an 8-minute Q&A session moderated by Redeye's analysts. You can ask your questions directly to Alzinova during the live broadcast in the question form available on the event page: https://www.redeye.se/events/870525/investor-forum-goteborg-16